N/A
Manufactured by Haleon US Holdings LLC
37,042 FDA adverse event reports analyzed
Last updated: 2026-04-14
ACETAMINOPHEN, ASPIRIN, AND CAFFEINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Haleon US Holdings LLC. The most commonly reported adverse reactions for ACETAMINOPHEN, ASPIRIN, AND CAFFEINE include DRUG INEFFECTIVE, PRODUCT USE IN UNAPPROVED INDICATION, DRUG EFFECTIVE FOR UNAPPROVED INDICATION, HEADACHE, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ACETAMINOPHEN, ASPIRIN, AND CAFFEINE.
Out of 20,674 classified reports for ACETAMINOPHEN, ASPIRIN, AND CAFFEINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 37,042 FDA FAERS reports that mention ACETAMINOPHEN, ASPIRIN, AND CAFFEINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, PRODUCT USE IN UNAPPROVED INDICATION, DRUG EFFECTIVE FOR UNAPPROVED INDICATION, HEADACHE, NAUSEA, FATIGUE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Haleon US Holdings LLC in connection with ACETAMINOPHEN, ASPIRIN, AND CAFFEINE. Always verify the specific product and NDC with your pharmacist.